• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

String of successful trials in SLE: have we cracked the code?

作者信息

van Vollenhoven Ronald

机构信息

Amsterdam University Medical Center, Amsterdam, The Netherlands.

Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, The Netherlands.

出版信息

Lupus Sci Med. 2020 Jan 2;7(1):e000380. doi: 10.1136/lupus-2019-000380. eCollection 2020.

DOI:10.1136/lupus-2019-000380
PMID:32095250
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7008706/
Abstract
摘要

相似文献

1
String of successful trials in SLE: have we cracked the code?系统性红斑狼疮（SLE）一系列成功的试验：我们破解其中的奥秘了吗？
Lupus Sci Med. 2020 Jan 2;7(1):e000380. doi: 10.1136/lupus-2019-000380. eCollection 2020.
2
Update on clinical trials in systemic lupus erythematosus.系统性红斑狼疮临床试验的最新进展。
Curr Opin Rheumatol. 2016 Sep;28(5):477-87. doi: 10.1097/BOR.0000000000000311.
3
Belimumab for the treatment of systemic lupus erythematosus.贝利尤单抗用于治疗系统性红斑狼疮。
Expert Rev Clin Immunol. 2015 Feb;11(2):195-204. doi: 10.1586/1744666X.2015.996550. Epub 2014 Dec 29.
4
Established organ damage reduces belimumab efficacy in systemic lupus erythematosus.已有的器官损伤会降低贝利尤单抗在系统性红斑狼疮中的疗效。
Ann Rheum Dis. 2019 Jul;78(7):1006-1007. doi: 10.1136/annrheumdis-2018-214880. Epub 2019 Jan 4.
5
Targeted therapies in systemic lupus erythematosus: successes, failures and future.系统性红斑狼疮的靶向治疗：成功、失败与未来。
Ann Rheum Dis. 2011 Mar;70 Suppl 1:i64-i66. doi: 10.1136/ard.2010.142208.
6
Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus.狼疮低疾病活动状态（LLDAS）可区分系统性红斑狼疮贝鲁单抗 BLISS-52 和 BLISS-76 三期临床试验中的应答者。
Ann Rheum Dis. 2019 May;78(5):629-633. doi: 10.1136/annrheumdis-2018-214427. Epub 2019 Jan 24.
7
Lupus clinical development: will belimumab's approval catalyse a new paradigm for SLE drug development?狼疮的临床开发：贝利尤单抗的获批会催生出系统性红斑狼疮药物开发的新模式吗？
Expert Opin Biol Ther. 2014 Apr;14(4):491-501. doi: 10.1517/14712598.2014.884065. Epub 2014 Feb 3.
8
Targeted B cell therapies in the treatment of adult and pediatric systemic lupus erythematosus.靶向B细胞疗法在成人及儿童系统性红斑狼疮治疗中的应用
Lupus. 2016 Sep;25(10):1086-96. doi: 10.1177/0961203316652491.
9
Successful treatment of refractory lupus nephritis by the sequential use of rituximab and belimumab.利妥昔单抗和贝利尤单抗序贯使用成功治疗难治性狼疮性肾炎。
Joint Bone Spine. 2017 Mar;84(2):235-236. doi: 10.1016/j.jbspin.2016.01.008. Epub 2016 May 26.
10
Connective tissue diseases: Translating the effects of BAFF in SLE.结缔组织病：解读BAFF在系统性红斑狼疮中的作用
Nat Rev Rheumatol. 2010 Sep;6(9):503-4. doi: 10.1038/nrrheum.2010.136.

引用本文的文献

1
SLE is not a one-size-fits-all disease.SLE 不是一种一刀切的疾病。
J Exp Med. 2023 Jun 5;220(6). doi: 10.1084/jem.20230559. Epub 2023 Apr 25.
2
The Pathogenesis, Molecular Mechanisms, and Therapeutic Potential of the Interferon Pathway in Systemic Lupus Erythematosus and Other Autoimmune Diseases.系统性红斑狼疮和其他自身免疫性疾病中干扰素通路的发病机制、分子机制及治疗潜力。
Int J Mol Sci. 2021 Oct 19;22(20):11286. doi: 10.3390/ijms222011286.
3
Long-term outcomes in systemic lupus erythematosus: trends over time and major contributors.系统性红斑狼疮的长期结局：随时间变化的趋势和主要影响因素。
Rheumatology (Oxford). 2020 Dec 5;59(Suppl5):v29-v38. doi: 10.1093/rheumatology/keaa382.
4
Targeting the Protective Arm of the Renin-Angiotensin System to Reduce Systemic Lupus Erythematosus Related Pathologies in MRL Mice.靶向肾素-血管紧张素系统的保护臂以减轻 MRL 小鼠的系统性红斑狼疮相关病变。
Front Immunol. 2020 Jul 23;11:1572. doi: 10.3389/fimmu.2020.01572. eCollection 2020.

本文引用的文献

1
Trial of Anifrolumab in Active Systemic Lupus Erythematosus.阿尼鲁单抗治疗活动性系统性红斑狼疮的试验。
N Engl J Med. 2020 Jan 16;382(3):211-221. doi: 10.1056/NEJMoa1912196. Epub 2019 Dec 18.
2
First use of cenerimod, a selective S1P receptor modulator, for the treatment of SLE: a double-blind, randomised, placebo-controlled, proof-of-concept study.选择性S1P受体调节剂西尼莫德首次用于系统性红斑狼疮的治疗：一项双盲、随机、安慰剂对照的概念验证研究。
Lupus Sci Med. 2019 Nov 9;6(1):e000354. doi: 10.1136/lupus-2019-000354. eCollection 2019.
3
Outcome of participants with nephrotic syndrome in combined clinical trials of lupus nephritis.狼疮性肾炎联合临床试验中肾病综合征参与者的结局
Lupus Sci Med. 2019 Feb 4;6(1):e000308. doi: 10.1136/lupus-2018-000308. eCollection 2019.
4
Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study.乌司奴单抗，一种白细胞介素 12 和白细胞介素 23 抑制剂，在活动性系统性红斑狼疮患者中的疗效和安全性：一项多中心、双盲、2 期、随机、对照研究的结果。
Lancet. 2018 Oct 13;392(10155):1330-1339. doi: 10.1016/S0140-6736(18)32167-6. Epub 2018 Sep 21.
5
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial.巴利昔替尼治疗系统性红斑狼疮：一项双盲、随机、安慰剂对照、2 期临床试验。
Lancet. 2018 Jul 21;392(10143):222-231. doi: 10.1016/S0140-6736(18)31363-1.
6
Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus.阿尼鲁单抗（一种用于治疗系统性红斑狼疮的全人源抗干扰素受体拮抗剂抗体）的特性研究
Lupus Sci Med. 2018 Apr 5;5(1):e000261. doi: 10.1136/lupus-2018-000261. eCollection 2018.
7
Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.皮下注射塔巴鲁单抗治疗系统性红斑狼疮的疗效和安全性：ILLUMINATE-1 研究 52 周结果，一项多中心、随机、双盲、安慰剂对照的 III 期临床研究。
Ann Rheum Dis. 2016 Feb;75(2):323-31. doi: 10.1136/annrheumdis-2015-207653. Epub 2015 Sep 3.
8
Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.皮下注射靶向 B 细胞激活因子的单克隆抗体塔布单抗治疗系统性红斑狼疮的疗效和安全性：来自 ILLUMINATE-2 的 52 周、III 期、多中心、随机、双盲、安慰剂对照研究结果。
Ann Rheum Dis. 2016 Feb;75(2):332-40. doi: 10.1136/annrheumdis-2015-207654. Epub 2015 Aug 20.
9
Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE.贝利尤单抗治疗对肾脏结局的影响：来自 SLE 患者的 3 期贝利尤单抗临床试验结果。
Lupus. 2013 Jan;22(1):63-72. doi: 10.1177/0961203312465781.
10
Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study.利妥昔单抗治疗活动性增殖性狼疮性肾炎患者的疗效和安全性：利妥昔单抗狼疮性肾炎评估研究
Arthritis Rheum. 2012 Apr;64(4):1215-26. doi: 10.1002/art.34359. Epub 2012 Jan 9.